Silibinin Reduces the Impact of Obesity on Invasive Liver Cancer

References

• CDC Global Cancer Statistics. https://www.cdc.gov/cancer/international/statistics.htm.
   Google Scholar
• CDC Adult Obesity Facts. https://www.cdc.gov/obesity/data/adult.html.
   Google Scholar
• Jiang C, et al.: Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J Gastroenterol 20, 16464–16473, 2014.
   PubMed Web of Science ®Google Scholar
• Zhao J and Lawless M: Stop feeding cancer: Pro-inflammatory role of visceral adiposity in liver cancer. Cytokine 64, 626–637, 2013.
   PubMed Web of Science ®Google Scholar
• Muriel P: Role of free radicals in liver disease. Hepatol Int 3, 526–536, 2009.
   PubMed Web of Science ®Google Scholar
• Jaeschke H: Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts. J Gastroenterol Hepatol 26, 173–179, 2011.
   PubMed Web of Science ®Google Scholar
• Bechmann L, et al.: The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatology 56, 952–964, 2012.
   PubMed Web of Science ®Google Scholar
• Taniguchi K and Karin M: IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 26, 54–74, 2014.
   PubMed Web of Science ®Google Scholar
• Thieringer F, et al.: Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma. Mol Carcinogenesis 51, 439–448, 2012.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang K, Song H, Wu M, Li J, et al.: Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism. Oncotarget 7, 32306–32317, 2016.
   PubMed Web of Science ®Google Scholar
• Sommer G, et al.: Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci 115, 13–23, 2008.
   PubMed Web of Science ®Google Scholar
• Choi Y, et al.: Involvement of visfatin in palmitate-induced upregulation of inflammatory cytokines in hepatocytes. Metabol Clin Exp 60, 1781–1789, 2011.
   PubMed Web of Science ®Google Scholar
• Pandey K and Rizvi S: Plant polyphenols as dietary antioxidants in human health and disease. Oxidative Med Cell Longevity 2, 270–278, 2009.
   PubMed Web of Science ®Google Scholar
• Liu Y, et al.: Inhibitory effect of blueberry polyphenolic compounds on oleic acid-induced hepatic steatosis in vitro. J Agric Food Chem 59, 12254–12263, 2011.
   PubMed Web of Science ®Google Scholar
• Deep G and Agarwal R: Anti-metastatic efficacy of silibinin: Molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 29, 447–463, 2014.
   Web of Science ®Google Scholar
• Ghasemi R, et al.: Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells. Nutr Cancer 65, 590–599, 2013.
   PubMed Web of Science ®Google Scholar
• Lin C, et al.: Silibinin inhibits the invasion of IL-6 stimulated colon cancer cells via selective JNK/AP-1/MMP-2 modulation in vitro. J Agric Food Chem 60, 12451–12457, 2012.
   PubMed Web of Science ®Google Scholar
• Gu M, et al.: Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor. Front Pharmacol 7, 345, 2016.
   PubMed Web of Science ®Google Scholar
• Federico A, et al.: Silybin-phosphatidylcholine complex protects human gastric and liver cells from oxidative stress. In Vivo 29(5), 569–575, 2015.
   PubMed Web of Science ®Google Scholar
• Detaille D, et al.: Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci. 82(21-22), 1070–1076, 2008.
   PubMed Web of Science ®Google Scholar
• Wu JW, Lin LC, Hung SC, Chi CW, and Tsai TH: Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal 45(4), 635–641, 2007.
   PubMed Web of Science ®Google Scholar
• Zhao J and Agarwal R: Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis, 20, 2101–2108, 1999.
   PubMed Web of Science ®Google Scholar
• Marengo A, Rosso C, and Bugianesi: Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med 67, 103–117, 2016.
   PubMed Web of Science ®Google Scholar
• Ramirez A, et al.: Incidence and risk factors for hepatocellular carcinoma in Texas Latinos: implications for prevention research. PLoS One 7, e35573, 2012.
   PubMed Web of Science ®Google Scholar
• Steppan C, et al.: The hormone resistin links obesity to diabetes. Nature 18, 307–312, 2001.
   Web of Science ®Google Scholar
• Tarkowski A, Bjersing J, Shestakov A, and Bokarewa M: Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 14, 1419–1431, 2010.
   PubMed Web of Science ®Google Scholar
• Lee J, et al.: Resistin, a fat-derived secretory factor, promotes metastasis of MDA-MB-231 human breast cancer cells through ERM activation. Nature 6, 18923, 2016.
   Google Scholar
• Allott E, et al.: MMP-9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation. Mol Carcinogenesis 52, 144–154, 2013.
   PubMed Web of Science ®Google Scholar
• Price RS, Cavazos D a, De Angel RE, Hursting SD, and deGraffenried L: Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis 15(2), 135–143, 2012.
   PubMed Web of Science ®Google Scholar
• Donohoe C, Lysaght J, O'Sullivan J, and Reynolds J: Emerging concepts linking obesity with the hallmarks of cancer. Trends Endocrinol Metabolism 28, 46–62, 2017.
   PubMed Web of Science ®Google Scholar
• Besten G, et al.: Short-chain fatty acids protect against high fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes 64, 2398–2408, 2015.
   PubMed Web of Science ®Google Scholar
• Park EJ, et al.: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 140, 197–208, 2010.
   PubMed Web of Science ®Google Scholar
• Lee YH and Pratley RE: The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep, 5, 70–75, 2005
   PubMedGoogle Scholar
• Wang Y, Ausman LM, Greenberg AS, Russell RM, and Wang XD. Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats. Int J Cancer 124, 540–546, 2009.
   PubMed Web of Science ®Google Scholar
• Umemura A, et al.: Liver Damage, inflammation and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metabolism 20(1), 133–144, 2014.
   PubMed Web of Science ®Google Scholar
• Chien ST, Shi MD, Lee YC, Te CC, and Shih YW: Galangin, a novel dietary flavonoid, attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells. Cancer Cell Int. 15, 15, 2015.
   PubMed Web of Science ®Google Scholar